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Objectives: To assess the impact of a personalized diet, with or without addition of VSL#3 preparation, on
biomarkers of inﬂammation, nutrition, oxidative stress and intestinal microbiota in 62 healthy persons
aged 65e85 years.
Design: Open label, randomized, multicenter study. Primary endpoint: High-sensitivity C-reactive protein.
Setting: Community.
Interventions: Eight week web-based dietary advice (RISTOMED platform) alone or with supplementa-
tion of VSL#3 (2 capsules per day). The RISTOMED diet was optimized to reduce inﬂammation and
oxidative stress.
Measurements: Blood and stool samples were collected on days 1 and 56.
Results: Diet alone reduced ESR (p ¼ 0.02), plasma levels of cholesterol (p < 0.01) and glucose (p ¼ 0.03).
Addition of VSL#3 reduced ESR (p ¼ 0.05) and improved folate (p ¼ 0.007), vitamin B12 (p ¼ 0.001) and
homocysteine (p < 0.001) plasma levels. Neither intervention demonstrated any further effects on
inﬂammation. Subgroup analysis showed 40 participants without signs of low-grade inﬂammation
(hsCRP<3 mg/l, subgroup 1) and 21 participants with low-grade inﬂammation at baseline (hsCRP3 mg/
l, subgroup 2). In subgroup 2 addition of VSL#3 increased biﬁdobacteria (p ¼ 0.005) in more participants
and improved both folate (p ¼ 0.015) and vitamin B12 (p ¼ 0.035) levels compared with subgroup 1. The
increases were positively correlated to the change in the biﬁdobacteria concentration for folate
(p ¼ 0.023) and vitamin B12 (p ¼ 0.001). As expected change in homocysteine correlated negatively to
change in folate (r ¼ 0.629, p ¼ 0.002) and vitamin B12 (r ¼ 0.482, p ¼ 0.026).y of Applied Sciences Neubrandenburg, Department of Agriculture and Food Technology, Section of Dietetics, Brodaer
5 5693 2512.
ini@gmx.net (L. Valentini).
Ltd and European Society for Clinical Nutrition and Metabolism. This is an open access article under the CC BY-NC-SA
/3.0/).
L. Valentini et al. / Clinical Nutrition 34 (2015) 593e602594Conclusions: Addition of VSL#3 increased biﬁdobacteria and supported adequate folate and vitamin B12
concentrations in subjects with low-grade inﬂammation. Decrease in homocysteine with VSL#3 was
clinically relevant. suggesting protective potentials for aging-associated conditions, e.g. cardiovascular or
neurological diseases.
ClinicalTrials.gov: NCT01069445eNCT01179789.
© 2014 The Authors. Published by Elsevier Ltd and European Society for Clinical Nutrition and
Metabolism. This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/
licenses/by-nc-sa/3.0/).1. Introduction
Aging is associated with a general increase in inﬂammation, as
measured by an increase in C-reactive protein and pro-
inﬂammatory cytokines [1,2]. This phenomenon has been termed
‘inﬂamm-aging’, and is characterized by a chronic, low-grade pro-
inﬂammatory condition leading to long-term tissue damage [3].
Increased inﬂammatory markers are associated with frailty and
mortality [1,4e6]. Reducing low-grade inﬂammation may be a way
to prevent or reduce the onset and the severity of some age-related
diseases, such as Alzheimer's disease, Parkinson's disease, athero-
sclerosis, type 2 diabetes, osteoporosis, cognitive decline and gen-
eral frailty. Oxidative stress, caused by accumulated cellular
damage from reactive oxygen species, plays an important role in
the aging process and is one of the primary causal factors in pro-
ducing a chronic state of inﬂammation [2].
Aging deeply affects the homeostasis of the gut microbiota
through changes in diet and lifestyle and age-related changes in gut
physiology. Gut microbiota can directly inﬂuence host wellbeing by
providing nutritional, metabolic and immunological beneﬁts [7],
such as the synthesis of folate and vitamin B12 [8], two critical
vitamins in aging people [9]. It has been proposed that age-related
changes in gut microbiota, associated with an increase in systemic
inﬂammation [10], may also contribute to the progression of dis-
ease and frailty in older people [11].
Evidence exists that inﬂammation [12], oxidative stress [13] and
gut microbiota [7,14] are inﬂuenced by diet, and it may therefore be
possible to reduce or delay the effects of age-related changes in
these parameters through appropriate dietary intervention and/or
use of nutraceutical dietary supplements.
The RISTOMED project aimed to use diet as a means to improve
health-related quality of life for older people and to prevent aging-
related diseases. It promotes an optimized diet that delivers the
recommended daily requirement of nutrients, vitamins and min-
erals for older people recommended by WHO, and is designed to
reduce inﬂammation and oxidative stress by promoting a healthy
gut microbiota. The initiative is also investigating the utility of
speciﬁc nutraceutical supplements in improving the above-
mentioned parameters. RISTOMED operates via an internet-based
platform known as E-Health Dietary Services. The diet was
designed based on data from the literature indicating foods and
nutrients known or suspected to modulate oxidative stress, in-
ﬂammatory activity and gut microbiota composition in older sub-
jects. For a review and full details regarding the RISTOMED project,
see www.ristomed.eu.
In this paper, we report speciﬁcally on the effect of VSL#3 taken
concomitantly with the RISTOMED diet. VSL#3 has been marketed
for many years as a food supplement or medical food in Europe and
North America. Supplementation with VSL#3 has been associated
with symptomatic improvement in ulcerative colitis [15] and irri-
table bowel syndrome [16], and with a reduction in inﬂammatory
cytokines and measures of oxidative stress in a pilot study in pa-
tients with chronic liver disease [17]. Recently, two large studies
have shown a reduced incidence of, or better recovery from, hepaticencephalopathy in cirrhotic patients after 3-month intervention
with VSL#3 [18,19].
The primary objective of the study was to investigate whether
an optimized diet alone or in conjunction with VSL#3 can decrease
high-sensitivity C-reactive protein (hsCRP) plasma concentration in
older people. HsCRP was chosen as internationally recognized
biomarker of low-grade inﬂammation and cardiovascular risk [20].
Secondary objectives included the interventional effects on gut
microbiota composition, oxidative stress and nutritional parame-
ters. Based on the secondary hypothesis that dietary interventions
might be more effective in stress situations compared to the
physiological state we additionally performed subgroup evalua-
tions in participants with existing low-grade inﬂammation.
2. Patients and methods
2.1. RISTOMED study design
RISTOMED was an open label, randomized, controlled trial with
four parallel arms, conducted at three centers in France (CHU,
Bordeaux), Germany (Charite, Berlin) and Italy (La Sapienza, Roma).
Participants were enrolled between May 2009 and April 2010 and
were randomized to one of four study arms: ‘Optimal diet for the
elderly’ alone; or ‘Optimal diet’ in conjunctionwith argan oil, VSL#3
bacterial blend, or AISA 5203-L fruit extract terpene, respectively.
The randomization was performed in Bologna by a centralized
computer-generated random number list, and stratiﬁed by
recruitment center and gender. Each recruitment center received a
list with consecutive participants codes for men and women (Italy:
M101-M124 and F101-F124; Bordeaux:M201-M224 and F201-F224;
Berlin: M301-M324 and F301-F324) together with closed envelopes
containing the random allocation for each participant code. The
participants were enrolled by the principal investigator at each site.
The study was conducted in accordance with International Good
Clinical Practice guidelines (ICH, May 1977), the Declaration of
Helsinki, and national laws and regulations. The study protocol was
approved by the ethics committee at each recruiting institution. The
participants gave written informed consent at enrollment. The
study was conducted under the 7th Framework Programme of the
European Commission (FP7-SME-2007-1, grant agreement
222230), and is registered at ClinicalTrials.gov, identiﬁers:
NCT01069445 (Bordeaux) and NCT01179789 (Berlin).
This report presents the results of the study with respect to the
comparison of the RISTOMED diet alone (Arm A) or combined with
VSL#3 bacterial blend (Arm B). The data relating to argan oil and
AISA 5203-L fruit extract terpene will be reported separately.
2.2. Participants
Eligible participants were healthy individuals aged 65e85 years,
male or female, with BMI 22e30 kg/m2 and Eastern Cooperative
Oncology Group Performance Status (ECOG) performance status
0e2, able to use a computer and with access to the internet, by
themselves or with help. Exclusion criteria were assessed through
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of conditions including anorexia, chronic severe diseases (cardiac,
lung, renal or neurological) and cancers, gastrointestinal diseases
requiring treatment, diabetes mellitus, current infection and anti-
biotic treatment, or anti-inﬂammatory drugs within the previous
four months, and any diseases or medications that could interfere
with study outcome measures. Intake of conventional yoghurt,
probiotics, prebiotics and symbiotics or other supposed functional
foods (vitamin- or mineral supplementation, nutritional supple-
ments in general) within the previous three weeks was disallowed.
Participants were withdrawn from the study if they had more than
one day per week or 4 days per month of non-compliance to the
assigned diet, used disallowed food/nutraceutical supplementa-
tion, or experienced concomitant diseases requiring treatment
with antibiotics or anti-inﬂammatory drugs. Those completing the
study were counted as the per-protocol population.
2.3. Dietary interventions
Each participant received a personal login to the RISTOMEDweb
platform, and was trained by a dietitian to use the personalized diet
platform. The platform organized the diet for participants, tailoring
a complete menu with recipes throughout the treatment period
and adapting and personalizing the diet individually. The technical
organization of the platform is shown in Fig. S1. The diet alone or
the diet plus VSL#3 supplementationwas administered for 8 weeks
(56 ± 2 days).
‘Optimized diet’: All participants received a personalized diet
plan formulated by a registered dietitian via the RISTOMED internet
platform. The diet varied between the three centers to reﬂect local
(country-speciﬁc) food customs and preferences, and also took into
account participants' personal preferences. After comparing the
main population reference intakes of macronutrients, vitamins and
minerals in older persons published by national and international
scientiﬁc organizations it was decided to use the reference values
for older people set out by the WHO (http://whqlibdoc.who.int/
publications/9241562102.pdf) for a joint census between the
three participating countries. Thereby, the diet for all countries
speciﬁed an intake of vitamins E and C, carotenoids, selenium and
zinc 30e150% higher than recommended levels, an intake of
polyphenols >400 mg/day, an n6:n3 polyunsaturated fatty acid
ratio of 3:1, and a ﬁber intake of 35 g/day with a ratio of soluble to
insoluble ﬁber of 1:1. Weekly intake frequencies for each food
group were recommended. The energy requirement of each
participant was estimated according to the individual Total Daily
Energy Expenditure (TDEE) to maintain the actual body weight
using two different methods: if the weight was steady (varia-
tion < 5%) in the last 3 months, TDEE was obtained from the
habitual dietary energy intake, while if the weight had changed
(variation > 5%) the TDEE was calculated by multiplying the resting
energy expenditure estimated by Harris-Benedict equation by the
Physical Activity Level (PAL) estimated by the International Physical
Activity Questionnaire (IPAC, www.ipaq.ki.se/downloads.htm).
Weight was monitored weekly and the diet was amended when
variations were observed. Compliance with the diet was controlled
by the self-reported intake on the RISTOMED web platform.
2.3.1. VSL#3 bacterial blend (VSL#3®, supplied by ACTIAL
Farmaceutica Lda, Funchal, Portugal)
VSL#3 is formulated in vegetable capsules containing 112 billion
lyophilized bacteria consisting of the following strains: Biﬁdo-
bacterium infantis DSM 24737, Biﬁdobacterium longum DSM 24736,
Biﬁdobacterium breve DSM 24732, Lactobacillus acidophilus DSM
24735, Lactobacillus delbrückii ssp. bulgaricus DSM 24734, Lacto-
bacillus paracasei DSM 24733, Lactobacillus plantarum DSM 24730,and Streptococcus thermophilus DSM 24731, in deﬁned ratios. Ex-
cipients include microcrystalline cellulose, stearic acid, magnesium
stearate, silicon dioxide and coloring agent. VSL#3 was adminis-
tered orally, 2 capsules daily on an empty stomach (at least 30 min
before lunch and dinner).
2.4. Study outcomes
The aim of this study was to investigate the effect of a “healthy
diet” with or without a probiotic preparation on inﬂammation and
several nutritional parameters in clinically healthy older persons.
The primary outcome measure was the change from baseline in
hsCRP (high-sensitivity C-reactive protein) levels in each study
arm. HsCRP was selected as the primary outcome because it is an
internationally recognized marker of low-grade inﬂammation and
cardiovascular risk [20] Secondary outcomes included measures of
oxidative stress (including homocysteine and related parameters),
inﬂammatory status, and gut microbiota composition.
A range of clinical, anthropometric and laboratory parameters
were recorded at clinical visits at baseline and study end (56 days).
Compliance with the diet and VSL#3 supplementation was recor-
ded by each participant every day via the web platform, and
assessed via telephone interview on days 14 and 42 and at each
visit. Weight was self-reported weekly. Oxidative stress and in-
ﬂammatory status were measured using speciﬁc markers in blood
samples [21]. Plasma was obtained from blood within 30 min of
venipuncture by centrifugation at 2000 g for 20 min. It was
rapidly frozen and stored at80 C. Plasma levels of IL-6, IL-10, and
TNF-a trimer were measured by multiplex sandwich ELISA tech-
nology (SearchLight, Aushon Biosystems, Billerica, MA) according
to the manufacturer's instructions. Samples, standards, and re-
agents were dispensed in the plates using a standardized technique
employing a robotic liquid handling system with 16 channels
(Microlab® STAR, Hamilton Robotics, Reno, NV). Since changes in
the gut microbiota composition may be connected with “inﬂamm-
aging”, the fecal abundances of Clostridium cluster IV and biﬁdo-
bacteria were assessed using 16S rDNA gene-targeted qPCR. All
analyses were carried out using established protocols [20,22,23].
2.5. Statistical analysis
It was a priori determined that a sample size of 30 participants
per intervention group has a 90.3% power to detect a statistically
signiﬁcant result for hsCRP at the 0.05 level of alpha in a two-tailed
test. Assuming a dropout rate of 20%, 36 participants were recruited
per arm. Comparison of response rates between groups was per-
formed using a Chi-squared test and ManneWhitney U-test for
biochemical parameters. TheWilcoxon signed rank test was used to
compare the difference before and after dietary interventions of all
parameters for each diet.
All analyses were performed on the per-protocol population.
Since a reduction of inﬂammatory parameters could not be expected
in persons with no inﬂammation at the beginning, a sensitivity
analysis was performed after the main analysis in which the study
groups were then divided into a subgroup without vs. a subgroup
with low-grade inﬂammation, based on the hsCRP at the beginning
of the study. A cut-off of hsCRP 3 mg/l was used according to
previously published data [20]. Differences of inﬂammatory pa-
rameters before and after dietary interventions were analyzed by 2-
way analysis of variance (ANOVA) to investigate the effects on
inﬂammation. Two-way analysis of covariance (ANCOVA) was used
to correct for baseline difference in inﬂammatory parameters to
compare the intervention arms. Data analysis was performed using
the SPSS/Win programversion 20 (Spss Inc., Chicago, IL). The level of
statistical signiﬁcance was deﬁned by a two-tailed p value <0.05.
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3.1. Baseline data
A total of 69 participants were randomized, 24 at each center in
Italy and Germany (12 men and 12 women) and 21 in France (10
men and 11 women). Sixty-two participants completed the study
(18/24 in Italy, 20/21 in France and 24/24 in Germany), 29 males
and 33 females (the per-protocol population). Seven participants
discontinued, due to non-compliance (n ¼ 2) or onset of diseases
and/or pharmacological treatment not allowed during the study
(n ¼ 5). Among the per-protocol population, 31 subjects were
randomized to diet alone (Arm A) and 31 subjects to diet plus
VSL#3 (Arm B) (Fig. 1). Gut microbiota analyses were performed on
60 participants only, 30 subjects for Arm A and 30 subjects for Arm
B. No clinically relevant adverse effects which required intervention
or termination of the study were reported (Fig. 1). Compliance with
the intake of VSL#3 as controlled by pill counting was between 87
and 95% in the different centers.
Mean (±SD) age of participants was 70.1 ± 3.9 years, and mean
BMI was 26.8 ± 3.59 kg/m2, with no signiﬁcant differences in age,
BMI, sex or country distribution between study arms. Although the
diet was calculated for weight maintenance, participation in the
study induced minor before-and-after weight differences both in
Arm A (1.05 ± 1.89 kg, p ¼ 0.004) and in Arm B (0.57 ± 1.5 kg,
p ¼ 0.014). Interestingly, despite being clinically healthy, the ma-
jority of participants (n ¼ 21 in Arm A vs. n ¼ 22 in Arm B) had a
hsCRP value slightly increased above the normal range (1 mg/l) and* Dental infection (antibiotics) or breast oppression
** Sleep disturbance, stomach pain, inflammatory
Screened: N=128 
Diet alone (Arm A)  
n=34 
Included and randomized: n = 69 
Diet & V
n =35 
Excluded: n=3
Completed: n=31 
Adverse events: n=2* 
Comple
Adverse
Fig. 1. Flow chart o23 participants (n ¼ 12 in Arm A vs. n ¼ 11 in Arm B) had moder-
ately increased homocysteine concentrations (>12e30 mmol/l) at
the beginning of the study (Table 1). Otherwise only minor de-
viations from normal values were seen.
3.2. Changes of nutritional and inﬂammatory markers
Parameters analyzed from blood samples at baseline and study
end are shown in Table 1 for Arm A and Arm B. End-of-study values
are not directly comparable between arms because of baseline dif-
ferences. Arm A was associated with signiﬁcant decreases in
erythrocyte sedimentation rate (ESR) (p ¼ 0.02), total cholesterol
(p < 0.01) and blood glucose (p ¼ 0.03). Arm B did not signiﬁcantly
affect cholesterol or glucose, however it reduced ESR (p¼ 0.05) and
was associatedwith signiﬁcant increases in serum folate (p¼ 0.007)
and serum vitamin B12 (p ¼ 0.001), and a decrease in plasma ho-
mocysteine (p < 0.001). The decrease in homocysteine resulted in a
signiﬁcantly lowernumberof participantswithmoderatelyelevated
homocysteine concentrations in Arm B compared to Arm A at study
end (n¼ 3 vs. n¼ 11, chi¼ 5.599, p¼ 0.018). Apart from ESR, neither
intervention showed effects on inﬂammatory parameters, including
the primary endpoint hsCRP, even when ANCOVA was used to
correct for baseline differences (not shown).
3.3. Biomarkers of oxidative stress
Baseline value distributions of oxidative stress markers were
scattered. No signiﬁcant changes from baseline in total antioxidant drug for more than 3 days 
 state (anti-inflammatory drug) 
Not included: n=56 
BMI (too high): 13 
Refusal: 15 
Diabetes mellitus: 5 
Depression: 2 
Lack of internet access: 12 
Severe disease 4 
Age (too young):2 
Intake of antibiotics: 2 
Intake of anti-inflammatory drug:1
Excluded: n=4 
SL#3 (Arm B)  
ted: n =31 
 events: n=3** 
f participants.
Table 1
Analysis of nutritional and inﬂammatory markers at baseline and study end (day 56).
Normal range ARM A (diet) ARM B (diet plus VLS#3)
Baseline Day 56 P Baseline Day 56 P
Nutritional markers
Hemoglobin (g/dl) 12e17.5 14.2 (0.2) 14.2 (0.3) ns 14.5 (0.2) 14.3 (0.2) ns
Total cholesterol (mg/dl) <200 215 (7.5) 202 (7.1) <0.01 227 (7.9) 221 (8.4) ns
Triglycerides (mg/dl) <180 120 (11.5) 116 (11.5) ns 113 (8.7) 112 (8.7) ns
Glucose (mg/dl) 55e110 94.5 (4.1) 91.5 (3.9) 0.03 92.5 (2.3) 95.1 (3.2) ns
Insulin (mU/ml) 2.6e24.9 9.0 (1.1) 9.8 (1.6) ns 8.9 (1.3) 8.1 (1.3) ns
Folate (ng/ml) 4.6e18.7 9.0 (0.7) 9.4 (0.6) ns 8.5 (0.6) 9.9 (0.6) 0.007
Vitamin B12 (ng/l) 195e865 417 (38.1) 426 (35.8) ns 403 (27.2) 437 (0.6) 0.001
Homocysteine (mmol/l) <10 11.5 (0.8) 11.8 (1.0) ns 11.2 (0.9) 9.5 (0.6) <0.001
Inﬂammatory markers
High sensitivity CRP (mg/l) <1.0 3.6 (0.6) 3.8 (4.5) ns 2.9 (0.7) 2.4 (0.4) ns
White blood cells (10*9/l) 4e10 6.1 (0.24) 5.9 (0.25) ns 6.0 (0.26) 6.2 (0.31) ns
ESR (mm/h) 20e30 24.9 (3.4) 18.9 (3.1) 0.02 23.3 (3.9) 17.8 (3.0) 0.05
Fibrinogen (mg/dl) 150e450 377 (17.3) 382 (13.4) ns 392 (19.3) 383 (22.1) ns
IL-6 (pg/ml) <20 29.9 (9.1) 34.7 (10.9) ns 12.3 (1.8) 17.7 (2.5) ns
TNF-a (pg/ml) <8.1 60.2 (27.7) 64.6 (28.0) ns 6.9 (3.3) 9.5 (4.2) ns
IL-10 (pg/ml) n.d. 5.3 (1.5) 7.6 (2.8) ns 3.5 (0.8) 3.5 (0.6) ns
Mean (SD). P ¼ pre-post difference with Wilcoxon signed rank test. n.d. not deﬁned. ESR ¼ erythrocyte sedimentation rate.
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thione (GSH), catalase, glutathione reductase, glutathione peroxi-
dase activity were observed in either study arm. Both diet alone
and diet plus VSL#3 were associated with an increase in
glutathione-S-transferase activity. A signiﬁcant increase in super-
oxide dismutase activity was seen only in Arm A (Table S1, see
online supplement).3.4. Gut microbiota
The baseline levels of both Clostridium cluster IV and Biﬁdo-
bacterium spp. were not signiﬁcantly different between the two
intervention arms. A high interindividual variability was evident,
with baseline levels ranging from 1.35103 to 1.77 107 16S rDNA
copy number/ng stool DNA for clostridia and from 2.52 to
5.82  105 16S rDNA copy number/ng stool DNA for biﬁdobacteria
(Table S2, see online supplement). Overall no signiﬁcant changes in
the fecal abundances of either Clostridium cluster IV or Biﬁdo-
bacterium spp. were observed as a result of both interventions.
However, the proportion of subjects with increased/decreased
biﬁdobacterial concentration after intervention tended to be
different between the two study arms (Chi square, p ¼ 0.071). In
particular, biﬁdobacteria increased in 18/30 (60%) participants in
Arm B, with a mean 11.6-fold ratio. An opposite trend, with
decreasing values, was observed in 19/30 (63%) participants in Arm
A (Fig. 2, Fig. S2).Fig. 2. Number of participants with increase/decrease of biﬁdobacteria concentration
after both interventions. In the subgroup without inﬂammation, biﬁdobacteria
increased and decreased in similar numbers of participants. In participants with low-
grade inﬂammation, however, addition of VSL#3 (Arm B) was associated with an in-
crease of biﬁdobacteria in all participants, in contrast to the diet only arm.3.5. Subgroup analysis
In order to evaluate the response to the dietary interventions
according to inﬂammation status, participants were divided into
two groups according to baseline hsCRP. With a cut-off of hsCRP
3 mg/l we identiﬁed 40 individuals with no inﬂammation and 21
with low-grade inﬂammation at baseline. The two groups were
statistically signiﬁcantly different for hsCRP (p ¼ <0.001), ESR
(p ¼ 0.017), ﬁbrinogen (p ¼ 0.002) and IL-6 (p ¼ 0.010), but not for
TNF-a or IL-10 at baseline.
We thus compared the two subgroups and found a signiﬁcantly
higher decrease in hsCRP (p ¼ 0.024), but no signiﬁcant difference
in all other inﬂammatory parameters, in the subgroup with low-
grade inﬂammation (see Table 2). There was no treatment effect
on inﬂammatory markers within the inﬂammation subgroups.3.6. Low-grade inﬂammation and gut microbiota
We further analyzed the effect of diet alone and diet with VSL#3
on gutmicrobiota separately in the two inﬂammation subgroups. In
the group without inﬂammation, no consistent changes in the
concentration of biﬁdobacteria were seen. However, in the group
with low-grade inﬂammation all participants in Arm B (receiving
VSL#3) showed an increase in biﬁdobacteria, in contrast to par-
ticipants in Arm A (Fig. 2).
We further evaluated the mean change of the absolute gut
microbiota concentration and conﬁrmed the signiﬁcant increase of
biﬁdobacteria in the low-grade inﬂammation diet plus VSL#3
group. Furthermore, we observed statistical trends toward
increased Clostridium populations and decreased clostridium/biﬁ-
dobacteria (C/B) ratio (Table 3).
3.7. Correlation between low-grade inﬂammation, biﬁdobacteria
and folate, vitamin B12, and homocysteine
As known from the literature, biﬁdobacteria produce folate and
vitamin B12 [8]. Therefore, we evaluated the possible correlation
between changes in biﬁdobacteria and the two vitamins depending
Table 2
Change in inﬂammatory parameters.
hsCRP_diff.
(mg/l)
ESR_diff.
(mm/h)
Fibr_diff.
(mg/dl)
IL-6_diff.
(pg/ml)
TNFa_diff.
(pg/ml)
No inﬂammation (hsCRP <3 mg/l) Arm A
Diet
1.42 (5.0) 4.9 (11.3) 18.5 (58) 6.3 (16.8) 4.1 (21.2)
Arm B
DietþVSL#3
0.28 (1.4) 4.3 (13.7) 13,6 (133) 4.2 (13.7) 0.61 (3.9)
Low-grade inﬂammation (hsCRP ¼ 3e20 mg/l) Arm A
Diet
1.40 (4.6) 7.7 (14.7) 13.2 (83) 2.6 (18.9) 17.0 (53.5)
Arm B
DietþVSL#3
2.70 (7.06) 8.8 (16.7) 2.6 (85) 8.8 (15.4) 8.1 (20.4)
F-test 6.019 0.864 0.081 0.010 3.490
Sig 0.017 0.357 0.777 0.919 0.067
Mean before-after differences of inﬂammatory parameters in the subgroups without and with low-grade inﬂammation at baseline. Arm A: diet alone, Arm B: diet þ VSL#3,
mean (SD).
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inﬂammation.
Figure 3 shows that before-after change in ArmA (diet alone) for
folate, vitamin B12 and homocysteine (Hcy) was similar in both
inﬂammation groups, however, in Arm B folate and vitamin B12
increased signiﬁcantly more in the low-grade inﬂammation group.
The decrease in homocysteine concentration did not correlate with
inﬂammation. However, diet with VSL#3 supplementation was
associated with more pronounced improvements (decreases) in
homocysteine compared to diet alone (p ¼ 0.007).
Figure 4 associates the before-after changes in folate, vitamin
B12 and homocysteine with changes in the concentration of biﬁ-
dobacteria. No correlation was observed in participants without
inﬂammation. However, in participants with low-grade inﬂam-
mation the changes in folate and vitamin B12 concentration were
positively associated with the change in the biﬁdobacteria
concentration.
Additionally (and not shown in Fig. 4), homocysteine was
negatively associated with folate (r ¼ 0.629, p ¼ 0.002) and
vitamin B12 serum concentrations (r ¼ 0.486, p ¼ 0.026) in the
low-grade inﬂammation group, suggesting a potential causal rela-
tionship between increased folate or vitamin B12 and decreased
homocysteine, as commonly described in the literature.
Diet plus VSL#3 showed a signiﬁcantly greater improvement of
homocysteine concentration compared to diet alone (p ¼ 0.026) in
the no inﬂammation group. In the low-grade inﬂammation group
the increase in folate (p ¼ 0.010) and vitamin B12 (p ¼ 0.016) was
signiﬁcantly higher with VSL#3 compared with diet alone, whereasTable 3
Mean change in gut microbiota concentration (delta day 56 e day 1) in all partici-
pants and in the subgroups with no inﬂammation (hsCRP < 3 mg/L) and low-grade
inﬂammation (hsCRP 3 mg/L) at baseline.
Number total
(arm A/Arm B)
Arm A (diet) Arm B
(diet þ VSL#3)
P-value
Biﬁdobacteria (log10 16S rDNA copy number/ng stool)
All 60 (30/30) 0.051 (0.782) 0.102 (0.772) 0.188
hsCRP < 3 mg/L 39 (17/22) 0.149 (0.750) 0.030 (0.837) 0.392
hsCRP ¼ 3e20 mg/L 21 (13/8) 0.078 (0.834) 0.467 (0.397) 0.020
Clostridium cluster IV (log10 16S rDNA copy number/ng stool)
All 60 (39/21) 0.073 (0.643) 0.008 (0.430) 0.723
hsCRP < 3 mg/L 39 (17/22) 0.105 (0.708) 0.062 (0.455) 0.769
hsCRP ¼ 3e20 mg/L 21 (13/8) 0.030 (0.571) 0.200 (0.296) 0.089
C/B ratio
All 60 (39/21) 0.123 (0.751) 0.095 (0.814) 0.101
hsCRP < 3 mg/L 39 (17/22) 0.254 (0.749) 0.032 (0.935) 0.292
hsCRP ¼ 3e20 mg/L 21 (13/8) 0.047 (0.748) 0.267 (0.280) 0.053
Gut microbiota results were log10 transformed for calculation. Results are depicted
as mean (SD). Two participants could not be analyzed: One in Arm B lacked hsCRP
values and one in Arm A lacked gut microbiota results.the change in homocysteine was similar in both study arms
(p ¼ 0.140).4. Discussion
This study demonstrated several interesting ﬁndings. First it
conﬁrmed previous epidemiologic evidence [24]. demonstrating
that a signiﬁcant proportion of healthy older people have elevated
hsCRP concentrations (3mg/l). This threshold is deﬁned as severe
cardiovascular risk by the American Heart Association [20] and
predicts a two-fold increased risk for myocardial infarction or
stroke. In absence of a generally agreed consensus, we chose this
hsCRP threshold to deﬁne low-grade inﬂammation.
Secondly, the study showed that eight weeks of the RISTOMED
web platform dietary intervention, with and without addition of
VSL#3, was able to modify several nutritional parameters like total
cholesterol, glucose and ESR. These are encouraging data suggesting
the opportunity to further develop such web-based diets, even for
older persons. However, the results for the primary outcome
parameter may appear disappointing at ﬁrst impression. Neither
intervention changed hsCRP concentration or any other analyzed
inﬂammatory parameter apart from ESR. This might not be sur-
prising considering that about two thirds of participants did not have
elevated inﬂammatory parameters at the beginning of the study.
Therefore we performed a subgroup analysis to investigate the
effects of dietary intervention with or without probiotic supple-
mentation in participants with low-grade inﬂammation. Interest-
ingly, the RISTOMED diet alone did not show signiﬁcant effects,
despite previous investigations showing that diet can improve
hsCRP concentration in similar populations [25]. It is still unclear
which dietary compounds contribute most to a reduction of in-
ﬂammatory parameters, therefore the composition of the RIS-
TOMED diet has to be reconsidered for future investigations.
With respect to oxidative stress, the RISTOMED diet improved
superoxide dismutase activity, indicating a better capacity to
scavenge superoxide anions. The addition of VSL#3 increased GST
activity without any other effect on oxidative stress [17]. The lack of
a signiﬁcant modiﬁcation in total antioxidant activity is not sur-
prising, because this parameter reﬂects the plasma redox state to
which many nutritional, genetic and environmental factors
contribute, often counterbalancing each other. In particular, the
activity of antioxidant enzymes may be affected by speciﬁc genetic
polymorphisms, and consequently, total antioxidant activity may
be modulated by a combination of these polymorphisms.
Notwithstanding the lack of alteration in total antioxidant activity,
the effect of VSL#3 on glutathione-S-tranferase activity globally
contributes to ameliorating the oxidative status of the subjects.
Fig. 3. Pre-post change of folate, vitamin B12 and homocysteine with and without low-grade inﬂammation. Low grade inﬂammation: hsCRP 3 mg/l; no inﬂammation: hsCRP
<3 mg/L at baseline. Numbers indicate p-values between respective groups (Mann Whitney U test). Hcy ¼ homocysteine.
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tween individuals, and no correlations with the inﬂammatory
status of the participants could be shown. In contrast to some
previous publications, no clear pattern of a composition was seen.
Concentrations of clostridia and biﬁdobacteria ranged from 103 to
107 per ng/stool. The two interventions did not signiﬁcantly affect
the fecal abundances of either Clostridium cluster IV or Biﬁdo-
bacterium spp. in the total group. Of note, to date conﬂicting data
have been published with respect to the proportions of biﬁdobac-
teria and Clostridium cluster IV in the gut microbiota of older per-
sons, as well as to the efﬁcacy of dietary interventions in
modulating microbiota composition and activity [26e28]. Howev-
er, most feeding trials with pre- and probiotics consistently indi-
cated an increase in fecal Biﬁdobacterium levels [26,28]. In the
present investigations, interestingly, all participants with low-
grade inﬂammation showed an increased biﬁdobacteria popula-
tion after VSL#3 intervention, and the mean increase was signiﬁ-
cantly higher compared with diet alone. These observations were
not made in participants without low-grade inﬂammation.
It must be noted that the study assessment did not include a
search for the speciﬁc bacterial strains found in VSL#3, so other
changes in colonization may have occurred but not been measured.
In addition, colonization is not the only parameter for evaluating
the clinical impact of probiotics, as they may exert their healthbeneﬁts through mechanisms of action different from alteration of
microbiota composition [26e28].
Interestingly, in the study population, diet plus VSL#3, but not
diet alone, was associated with a clinically relevant reduction in
homocysteine levels, and increased levels of folate and vitamin B12.
Both vitamins increased signiﬁcantly more in the subgroup with
low-grade inﬂammation. Raised homocysteine levels have been
identiﬁed in many epidemiological studies as an independent risk
factor for cardiovascular disease [29,30], and for stroke in patients
with pre-existing coronary heart disease [31]. High plasma levels of
homocysteine contribute approximately 10% of the thrombotic risk
in the general population [32], most probably in combination with
others risk factors, such as smoking and high blood pressure [33].
Thus, the reduction of homocysteine could indicate a potential role
for VSL#3 in reducing cardiovascular risk. Folate is involved in the
metabolism of homocysteine to methionine, and increased folate
levels are associated with homocysteine lowering [34]. Increased
folate was also associated with decreased homocysteine in the
present report, albeit only in the subgroup with low-grade
inﬂammation. Clinical studies have conﬁrmed the close relation-
ship between plasma homocysteine and folate [35e37], so that the
presence of hyperhomocysteinemia should be considered as an
index of folate deﬁciency from inadequate intake or absorption.
Inadequate intake is due to the low consumption of raw vegetables,
Fig. 4. Association between before-after changes in folate, vitamin B12 and homocysteine (Hcy) and changes in the amount of biﬁdobacteria. Stratiﬁed for participants without
inﬂammation (hsCRP < 3 mg/l)) and participants with existing low-grade inﬂammation (hsCRP 3e20 mg/l). Blue circles: group A (diet only); green circles: group B (diet þ VSL#3).
(For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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provides only about 100 mg per day of folic acid from non-vegetable
sources. However, about 300 mg/day are necessary to meet the
needs of healthy subjects, and thus folic acid has to be integrated
into the diet. Some degree of folate deﬁciency is very likely in older
persons due to reduced dietary intake and/or poor absorption.
Experimental studies suggest that it may be possible to use
certain strains of biﬁdobacteria to increase folate uptake, either
through their use in foods, such as fermented dairy products, or in
the intestine by administration as live bacterial supplements [38].
Several strains of biﬁdobacteria have been shown to produce folate
in the gut of rats, leading to increased plasma folate levels [39,40].
In a pilot study, three strains, belonging to Biﬁdobacterium ado-
lescentis and Biﬁdobacterium pseudocatenulatum species, were also
shown to synthesize and secrete folate in the human intestine [40].
Also, some strains of lactic acid bacteria are able to synthesize B
vitamins, and these could be used in fermentation to enhance the
vitamin content of cereal-based foodstuffs [41]. According to this,
the administration of Biﬁdobacterium and Lactobacillus spp.
included in VSL#3, along with the increase in the biﬁdobacterial
community detected at study end, may have contributed to provide
a complementary endogenous source of folate, leading to the in-
crease of serum folate levels in the diet plus VSL#3 study arm.
Currently we are unable to explainwhy relevant increases occurred
in the subgroup with low-grade inﬂammation only.
Vitamin B12 also has a homocysteine lowering effect. Sub-
clinical vitamin B12 deﬁciency is more prevalent in older persons
than in the general population. The age-related decline in the
production of gastric acids results in decreased release of vitamin
B12 from protein in the food and thus decreased bioavailability
[42]. Subclinical vitamin B12 deﬁciency has been associated with
increased risk of frailty in several epidemiological studies [43,44].Supplementation to increase levels of folate and vitamin B12 is
also associated with reduced risk of age-related macular degen-
eration [45]. There is some evidence suggesting a possible asso-
ciation between low vitamin B12 levels and cognitive decline,
although more work is needed to conﬁrm this [34,46,47]. Com-
bined folate and vitamin B12 supplementation has recently been
shown to improve cognitive functioning in older people with
depression [48].
This study has two possible methodological limitations. Firstly,
it was an open label study without a placebo arm; secondly, it used
biological instead of clinical endpoints. We still believe that the
results are valuable since it is very unlikely that endpoints like
intestinal microbiota or inﬂammatory parameters might be inﬂu-
enced by the knowledge of the composition of the supplement.
Furthermore these biological endpoints, although they may be
considered surrogate endpoints, are generally accepted indicators
for clinical endpoints, which might only be observed with a much
longer follow-up time. Nevertheless, this study gives important
information about new approaches to improve the diet for older
persons.
Another limitationmight be seen in not analyzing biomarkers of
intake, such as serum concentrations of vitamins E or C, caroten-
oids, selenium, zinc or PUFAs, although they could have been useful
to verify the compliance to RISTOMED diet. Nevertheless, dietary
compliance was monitored and strengthened through nutritional
counseling byweekly phone calls and every 4 weeks by ambulatory
follow-ups; moreover the subjects were encouraged to record on
the web-platform any changes about the prescribed diet.
We can not exclude that stricter dietary recommendations for
higher folate and B12 intake can result in increased concentrations
of both vitamins independent of VSL#3 intake. Nevertheless, both
arms followed the same RISTOMED diet; so the difference seen in
L. Valentini et al. / Clinical Nutrition 34 (2015) 593e602 601the current report emerges from the addition of VSL#3. To our
knowledge and suggested by a recent review [49] this is the ﬁrst
time that increased vitamin serum concentrations by intake of a
bacterial blend was observed in humans.
In conclusion, the RISTOMED web platform dietary intervention
in older adults is feasible, but dietary approaches that can be useful
to reduce low-grade inﬂammation must be reassessed for future
investigations. The reduction in homocysteine concentration and
the increase in folate and vitamin B12 seen with VSL#3 supple-
mentation in existing low-grade inﬂammation could potentially
reduce the risk of a range of age-related conditions. Long-term
studies are warranted to investigate whether VSL#3 can improve
or slow the decline of physical or cognitive function in older people,
and reduce cardiovascular risk.
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